iRhythm Brass Face Suit Over FDA's Heart Monitor Inquiry

By Katryna Perera · May 20, 2024, 6:22 PM EDT

Several current and former directors and executives of medical technology company iRhythm are named in a shareholder derivative suit alleging they failed to disclose an inquiry by the Food and Drug...

To view the full article, register now.

Try a seven day FREE Trial

Already a subscriber? Click here to login

Documents

Complaint

Case Information

Case Title

Ayers v. iRhythm Technologies, Inc. et al

Case Number

Court

Delaware

Nature of Suit

Securities/Commodities

Date Filed

May 17, 2024

Recent Articles By Katryna

June 06, 2024
White Collar Boutique Sued By Ex-Client Over Representation
June 04, 2024
Biotech RenovaCare Can't Beat Investors' Stock Promo Suit
June 03, 2024
Humana Hit With Investor Suit Over Post-COVID Costs
May 30, 2024
Veradigm Execs Sued Over Company's Nasdaq Delisting
May 02, 2024
Masimo Hit With Derivative Suit Over Audio Co. Acquisition
May 01, 2024
Insulin Pump Maker Wins Toss of Investor Suit For Now
April 30, 2024
Vaxart Investors Want Sanctions Over Deleted Texts
April 08, 2024
Walmart Beats Investor Suit Over Opioid Probe Disclosures
March 29, 2024
Hedge Fund Beats Vaxart Investor's 'Short-Swing' Profits Suit
March 18, 2024
Biotech Ardelyx Beats Shareholder Suit Over Kidney Drug